PIMCO Corporate & Income Opportunity Fund (PTY) Competitors

PIMCO Corporate & Income Opportunity Fund (NYSE:PTY) and iShares Biotechnology ETF (NASDAQ:IBB) are both mid-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Which has higher earnings and valuation, PTY or IBB?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PIMCO Corporate & Income Opportunity Fund	N/A	N/A	N/A	N/A	N/A
iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A

Which has more volatility & risk, PTY or IBB?

PIMCO Corporate & Income Opportunity Fund has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, iShares Biotechnology ETF has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in PTY or IBB?

10.3% of PIMCO Corporate & Income Opportunity Fund shares are owned by institutional investors. Comparatively, 62.5% of iShares Biotechnology ETF shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts prefer PTY or IBB?

Given iShares Biotechnology ETF's higher possible upside, analysts clearly believe iShares Biotechnology ETF is more favorable than PIMCO Corporate & Income Opportunity Fund.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PIMCO Corporate & Income Opportunity Fund	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
iShares Biotechnology ETF	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56

Does the media prefer PTY or IBB?

In the previous week, PIMCO Corporate & Income Opportunity Fund had 3 more articles in the media than iShares Biotechnology ETF. MarketBeat recorded 5 mentions for PIMCO Corporate & Income Opportunity Fund and 2 mentions for iShares Biotechnology ETF. PIMCO Corporate & Income Opportunity Fund's average media sentiment score of 1.17 beat iShares Biotechnology ETF's score of 0.38 indicating that PIMCO Corporate & Income Opportunity Fund is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PIMCO Corporate & Income Opportunity Fund	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iShares Biotechnology ETF	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is PTY or IBB a better dividend stock?

PIMCO Corporate & Income Opportunity Fund pays an annual dividend of $1.43 per share and has a dividend yield of 9.8%. iShares Biotechnology ETF pays an annual dividend of $0.41 per share and has a dividend yield of 0.3%.

Is PTY or IBB more profitable?

Company	Net Margins	Return on Equity	Return on Assets
PIMCO Corporate & Income Opportunity Fund	N/A	N/A	N/A
iShares Biotechnology ETF	N/A	N/A	N/A

Does the MarketBeat Community believe in PTY or IBB?

iShares Biotechnology ETF received 35 more outperform votes than PIMCO Corporate & Income Opportunity Fund when rated by MarketBeat users. Likewise, 67.09% of users gave iShares Biotechnology ETF an outperform vote while only 64.92% of users gave PIMCO Corporate & Income Opportunity Fund an outperform vote.

Company	Underperform	Outperform
PIMCO Corporate & Income Opportunity Fund	Outperform Votes 124 64.92%	Underperform Votes 67 35.08%
iShares Biotechnology ETF	Outperform Votes 159 67.09%	Underperform Votes 78 32.91%

Summary

iShares Biotechnology ETF beats PIMCO Corporate & Income Opportunity Fund on 5 of the 9 factors compared between the two stocks.